Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
EVOQ REMEDIES LIMITED |
End-of-day quote
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 12.19 INR | -0.49% | +1.58% | -14.15% | |
| Nov. 10 | Evoq Remedies Limited Reports Earnings Results for the Half Year Ended September 30, 2023 | CI |
| Sep. 11 | Evoq Remedies Limited Announces Resignation of Directors | CI |
| Sales 2023 | 264M 3.17M | Sales 2024 * | - | Capitalization | 177M 2.12M |
|---|---|---|---|---|---|
| Net income 2023 | 16M 192K | Net income 2024 * | - | EV / Sales 2023 | 1,03x |
| Net Debt 2023 | 94.23M 1.13M | Net cash position 2024 * | - 0 | EV / Sales 2024 * | - |
| P/E ratio 2023 | 10,9x | P/E ratio 2024 * | Employees | - | |
| Yield 2023 | - | Yield 2024 * |
-
| Free-Float | 26.47% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.21% | ||
| 1 week | +2.08% | ||
| Current month | -0.41% | ||
| 1 month | -8.51% | ||
| 3 months | -17.06% | ||
| 6 months | -7.55% | ||
| Current year | -13.73% |
1 week
12.00
12.49
1 month
11.3613.75
Current year
10.5018.49
1 year
10.5018.49
3 years
10.5025.00
5 years
10.5025.00
10 years
10.5025.00
| Managers | Title | Age | Since |
|---|---|---|---|
Bhumishth Patel
CEO | Chief Executive Officer | 40 | 2010 |
Yogesh M. Rajput
DFI | Director of Finance/CFO | - | 2022 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bhumishth Patel
CEO | Chief Executive Officer | 40 | 2010 |
| Director/Board Member | 32 | 2022 | |
| Director/Board Member | 29 | 2022 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-05 | 12.19 | -0.49% | 16 000 |
| 23-12-05 | 12.25 | -1.21% | 16,000 |
| 23-12-04 | 12.4 | +1.22% | 8,000 |
| 23-12-01 | 12.25 | -0.41% | 4,000 |
| 23-11-30 | 12.3 | -1.28% | 36,000 |
End-of-day quote Bombay Stock Exchange, December 04, 2023
More quotes
EVOQ Remedies Limited is an India-based company, which is a manufacturer and supplier of pharmaceutical products. The Company is engaged in the pharmaceutical business involving marketing, trading, and distribution of a range of pharmaceutical formulation products, such as antibiotic drugs, anti-malarial drugs, anti-allergic and cold drugs, analgesic/antipyretic and anti-inflammatory drugs, dermatology products, cerebral activator drugs, neurological drugs, gastrointestinal drugs, steroids, gynecology drugs, calcium, multivitamins, antioxidants, and injections. It offers a range of pharmaceutical formulation products, of which around 120 products are marketed by the Company under its own brand name. It also deals in the trading of active pharmaceutical ingredients (APIs). Its products include Abacavir Sulphate, Acetazolamide, Acyclovir, Adefovir Dipivoxil Allylestrenole, Alpha Beta Arteether, Alpha Lipoic Acid, Alprazolam , Amoxycillin Trihydrate, Ampicillin Trihydrate, and more.
Sector
Pharmaceuticals
Calendar
2024-05-26
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -13.73% | 2 M $ | |
| +60.77% | 529 B $ | |
| +47.08% | 444 B $ | |
| -10.25% | 382 B $ | |
| -4.25% | 269 B $ | |
| -10.54% | 255 B $ | |
| -13.65% | 231 B $ | |
| +2.08% | 200 B $ | |
| -9.11% | 198 B $ | |
| -43.23% | 164 B $ |
